.jpg)
Pfizer is set to acquire Seagen for $43 billion and create a new oncology division
13 Dec 2023
In a significant move, Pfizer has announced its anticipation of concluding the $43 billion deal to acquire cancer drug maker Seagen by 16 December 2023.
Moderna sues Pfizer-BioNtech for patent violation
02 Sep 2022
According to Moderna, Pfizer-BioNTech copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged in 2019
Pfizer eyes a market gatecrash as India’s Covid tally mounts
04 May 2021
US pharma giant Pfizer is trying to convince Indian authorities that there is no need for regulatory scrutiny for its corona virus vaccine that added $3.5 billion to its revenue in the first three months of this year, since it is approved by regulatory authorities in the US, Britain, Japan and the WHO, all of which India endorses
Pfizer to acquire cancer drug maker Array Biopharma for $10.6 bn
18 Jun 2019
Array’s Braftovi and Mektovi, launched last July for the deadliest form of skin cancer at a price of $22,000 per month, had sales of around $72 million over their first nine months, besides revenue from royalty and licensing deals
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Pfizer from Informachine
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
11 Dec 2025
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ma
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
09 Dec 2025
Augments Pfizer’s efforts to advance investigational medicines for cardiometabolic diseases Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license ag
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
09 Dec 2025
Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood Pfizer Inc. (NYSE: PFE) today presented results from the
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
22 Nov 2025
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patien
Pfizer Completes Acquisition of Metsera
14 Nov 2025
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer’s Internal Medicine portfolio Positions P
Pfizer Responds to Delaware Chancery Court Ruling
08 Nov 2025
Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. f
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
01 Nov 2025
Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach o
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
01 Nov 2025
Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
Pfizer Addresses Proposal for Metsera
30 Oct 2025
Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant marke
Pfizer shares new survival data in non-metastatic prostate cancer
22 Oct 2025
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk
